Logo
x

Search

Subscribe Now

extensive-stage small cell lung cancer

AstraZeneca's Imfinzi (durvalumab) Receives EC's Approval as 1L Treatment for Extensive-Stage Small Cell Lung Cancer

AstraZeneca's Imfinzi (durvalumab) Receives EC's Approval as 1L Treatment for Extensive-Stage Small Cell Lung Cancer

  • September 2, 2020
AstraZeneca's Imfinzi (durvalumab) Receives the US FDA's Approval for Extensive-Stage Small Cell Lung Cancer

AstraZeneca's Imfinzi (durvalumab) Receives the US FDA's Approval for Extensive-Stage Small Cell Lung Cancer

  • March 30, 2020
Roche's Tecentriq (atezolizumab) + CT Receive NMPA's Approval as 1L Treatment for Extensive-Stage Small Cell Lung Cancer

Roche's Tecentriq (atezolizumab) + CT Receive NMPA's Approval as 1L Treatment for Extensive-Stage Small Cell Lung Cancer

  • February 14, 2020
AstraZeneca Reports the US FDA Acceptance of sBLA and Granted Priority Review for Imfinzi (durvalumab) to Treat Patients with Extensive-Stage Small Cell Lung Cancer

AstraZeneca Reports the US FDA Acceptance of sBLA and Granted Priority Review for Imfinzi (durvalumab) to Treat Patients with Exte...

  • November 29, 2019
Henlius Reports EMA’s Validation of MAA for Hansizhuang (serplulimab) as 1L Treatment of Extensive-Stage Small Cell Lung Cancer

    Henlius Reports EMA’s Validation of MAA for Hansizhuang (serplulimab) as 1L Treatment of Extensive-Stage Small Cell Lung Cancer

    • March 23, 2023
    Henlius Entered into an Exclusive License Agreement with Fosun Pharma for HANSIZHUANG in the US

      Henlius Entered into an Exclusive License Agreement with Fosun Pharma for HANSIZHUANG in the US

      • December 28, 2022
      Shanghai Henlius Biotech Reports First Patient Dosing of Hansizhuang for Extensive-Stage Small Cell Lung Cancer Treatment in the US

        Shanghai Henlius Biotech Reports First Patient Dosing of Hansizhuang for Extensive-Stage Small Cell Lung Cancer Treatment in the U...

        • November 30, 2022
        Jazz First Patient Enrolled in P-III (IMforte) Trial of Zepzelca (lurbinectedin) + Tecentriq for Extensive-Stage Small Cell Lung Cancer

          Jazz First Patient Enrolled in P-III (IMforte) Trial of Zepzelca (lurbinectedin) + Tecentriq for Extensive-Stage Small Cell Lung C...

          • December 1, 2021
          AstraZeneca

            AstraZeneca's Imfinzi (durvalumab) Receives EC's Approval as 1L Treatment for Extensive-Stage Small Cell Lung Cancer

            • September 2, 2020
            AstraZeneca

              AstraZeneca's Imfinzi (durvalumab) Receives the US FDA's Approval for Extensive-Stage Small Cell Lung Cancer

              • March 30, 2020
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.